Reck M, et al. - In view of the phase III CheckMate 227 study that showed significantly prolonged progression-free survival (co-primary end-point) with first-line nivolumab + ipilimumab vs chemotherapy in patients with advanced non–small-cell lung cancer and high tumor mutational burden (≥10 mutations/megabase), researchers examined this population for patient-reported outcomes. They used the validated PRO questionnaires Lung Cancer Symptom Scale (LCSS) and EQ-5D to assess disease-related symptoms and general health status, respectively. They performed a descriptive analysis of LCSS average symptom burden index and three-item global index and EQ-5D visual analogue scale and utility index scores and changes from baseline. They noted improved patient-reported outcomes with nivolumab + ipilimumab vs chemotherapy in non–small-cell lung cancer. Improvements in lung cancer symptoms and general health status were rapid and durable with nivolumab + ipilimumab. In addition, a delay was observed in disease-related symptom deterioration with nivolumab + ipilimumab.